Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) bet
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
07:44pm, Thursday, 12'th Feb 2026
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
06:45pm, Thursday, 12'th Feb 2026
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
04:30pm, Thursday, 12'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such invest
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ:
New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) bet
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – VTGN
05:00pm, Wednesday, 11'th Feb 2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 20
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired secur
LEVI & KORSINSKY, LLP ANNOUNCES SECURITIES CLASS ACTION FILED AGAINST VISTAGEN THERAPEUTICS UNDER FEDERAL SECURITIES LAWS
09:00am, Wednesday, 11'th Feb 2026
NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN). YOU MAY BE AFFECTED IF YOU: Pu
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:51am, Tuesday, 10'th Feb 2026
LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“
New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) betw
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
05:21pm, Monday, 09'th Feb 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired secur
